Aromatase inhibitors: the journey from the state of the art to clinical open questions
Breast cancer is a major cause of death among females. Great advances have been made in treating this disease, and aromatase inhibitors (AIs) have been recognized as the cornerstone. They are characterized by high efficacy and low toxicity. The authors reviewed the available literature and defined s...
Main Authors: | Daniele Generali, Rossana Berardi, Michele Caruso, Marina Cazzaniga, Ornella Garrone, Ida Minchella, Ida Paris, Carmine Pinto, Sabino De Placido |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1249160/full |
Similar Items
-
Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions
by: Daniele Generali, et al.
Published: (2024-01-01) -
Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time
by: Adnan Shaaban, et al.
Published: (2024-05-01) -
Aromatase inhibitors in the treatment of endometriosis
by: Radosław Słopień, et al.
Published: (2016-03-01) -
Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer
by: Li Huifang, et al.
Published: (2022-12-01) -
Long term effects of aromatase inhibitor treatment in patients with aromatase excess syndrome
by: Eleni Z. Giannopoulou, et al.
Published: (2024-11-01)